Results 291 to 300 of about 1,501,016 (387)

Deciphering the transcriptomic landscape of early HR+/HER2− breast cancer in very young women

Cancer Communications, EarlyView.
Iris Garrido‐Cano, Marta Tapia, Juan Carbonell, Carlos Peña, Sandra Torres‐Ruiz, Anna Ágreda‐Roca, Ana Lameirinhas, Cristina Tebar, Octavio Burgués, Cristina Hernando, Ana Lluch, Fara Brasó‐Maristany, Aleix Prat, Begoña Bermejo, María Teresa Martínez, Juan Miguel Cejalvo   +15 more
wiley   +1 more source

Evaluation of Potential Effects of CYP3A Inhibition and CYP3A Induction on the Pharmacokinetics of Fruquintinib in Healthy Subjects

Clinical Pharmacology in Drug Development, EarlyView.
Abstract Cytochrome P450 (CYP) 3A plays a significant role in fruquintinib metabolism in vitro. This 2‐part, 2‐period fixed‐sequence study investigated the impact of CYP3A inhibition (itraconazole) and CYP3A induction (rifampin) on the pharmacokinetics (PK) of fruquintinib and M11, its main metabolite.
Martha Gonzalez, Zhao Yang, William R Schelman, Xiaofei Zhou, Neeraj Gupta, Caly Chien   +5 more
wiley   +1 more source

A systematic review and network meta-analysis of interventions to preserve insulin-secreting beta cell function in people newly diagnosed with type 1 diabetes: results from randomised controlled trials of immunomodulatory therapies. [PDF]

BMC Med
Beese SE, Price MJ, Tomlinson C, Sharma P, Harris IM, Adriano A, Quinn LM, Gada R, Horgan TJ, Maggs F, Burrows M, Nirantharakumar K, Thomas GN, Andrews RC, Moore DJ, Narendran P.   +15 more
europepmc   +1 more source

Pharmacokinetics, Safety, and Tolerability of Single‐Dose Dazukibart in Healthy Adults in China and Japan: Results From 2 Randomized, Double‐Blind, Phase 1 Studies

Clinical Pharmacology in Drug Development, EarlyView.
Abstract Dazukibart is a humanized monoclonal antibody selectively targeting interferon‐β. The pharmacokinetics (PK), safety, tolerability, and immunogenicity of dazukibart were evaluated in 2 double‐blind, randomized, placebo‐controlled, single‐dose, Phase 1 studies in healthy adults in China (Study 1: N = 18; dazukibart 900 mg = 15; placebo = 3) and ...
Naihan Chen, Yamato Sano, Xiaohong Wang, Shuiyi Hu, Junichi Tabira, Xin Luo, Hiroki Yoshimatsu, John Prybylski, Myron Chu, Haiyan Li, Kenji Takazawa   +10 more
wiley   +1 more source

Comparison of the effects of inhalant furosemide, oxygen therapy, and placebo in patients with acute dyspnea referred to emergency departments by EMS in various hospitals in Tehran. [PDF]

Int J Emerg Med
Rezai M, Yarahmadi D, Mirkheshti M, Aghili M, Mosadegh R, Esfehani KJ, Abbasi S, Naseri Rad F.   +7 more
europepmc   +1 more source

Ascites of patients with solid tumors shows distinct inflammatory patterns

Cancer Communications, EarlyView.
Julia M. Berger, Martin Korpan, Carina Zierfuss, Katharina Syböck, Erwin Tomasich, Andreas Kienzle, Maria Koenig, Markus Kleinberger, Lynn Gottmann, Birgit Fendl, Cihan Ay, Johannes Pammer, Catharina Müller, Rudolf Oehler, Lorenz Balcar, Thomas Reiberger, Elisabeth S. Bergen, Barbara Niederdorfer, Matthias Preusser, Anna S. Berghoff   +19 more
wiley   +1 more source

Safety, Tolerability, and Pharmacokinetics of Donanemab in Healthy Chinese Participants: A Phase 1, Randomized, Double‐Blind, Placebo‐Controlled Study

Clinical Pharmacology in Drug Development, EarlyView.
Abstract Alzheimer's disease (AD), characterized by β‐amyloid (Aβ) plaques and neurofibrillary tangles, is the leading cause of dementia globally. Donanemab is a humanized immunoglobulin G1 in development as a treatment to slow AD progression. This study aimed to evaluate the safety, tolerability, pharmacokinetics (PKs), and immunogenicity of donanemab
Junyu Xu, Nan Zhao, Yihui Wang, Ivelina Gueorguieva, Chenxi Qian, Yimin Cui   +5 more
wiley   +1 more source

ProVag: the effect of oral probiotics on the vaginal microbiota composition in women receiving medical assisted reproduction in a Dutch fertility clinic - protocol of a randomised, placebo-controlled, double-blind study. [PDF]

BMJ Open
van Haren A, Morre SA, Stolaki M, de Jonge J, Stevens Brentjens L, van Golde R.   +5 more
europepmc   +1 more source

A Randomized Thorough QT Trial Using Concentration‐QT Analysis to Evaluate the Effects of Centanafadine on Cardiac Repolarization

Clinical Pharmacology in Drug Development, EarlyView.
Abstract Centanafadine is a norepinephrine/dopamine/serotonin reuptake inhibitor in development for treatment of attention‐deficit/hyperactivity disorder. This double‐blind, placebo‐ and moxifloxacin‐controlled, 3‐period crossover trial evaluated the effects of centanafadine (EB‐1020) and its metabolite (EB‐10601) on cardiac repolarization in 30 ...
Osman S. Turkoglu, Xiaofeng Wang, Jennifer Repella‐Gordon, Susan E. Shoaf   +3 more
wiley   +1 more source

Effect of attention bias modification on depressive affect. [PDF]

Sci Rep
Özdemir NÖ, Yüksel S.
europepmc   +1 more source